Literature DB >> 18600318

Absence of time-dependent artesunate pharmacokinetics in healthy subjects during 5-day oral administration.

L T Diem Thuy1, L Ngoc Hung, P T Danh, K Na-Bangchang.   

Abstract

AIM: The aim of the present study was to investigate the existence of time-dependent pharmacokinetics of artesunate (ARS) during 5 consecutive days of oral administration to 10 healthy Vietnamese subjects (aged 21-52 years and weighing 49-90 kg).
METHODS: Each volunteer received 200 mg oral doses of ARS once daily for 5 consecutive days. Blood samples (3 ml each) were collected on days 1 and 5 at 0 (before dosing), 0.5, 1, 2, 3, 4, and 6 h after drug administration. During days 2, 3, and 4, the same volumes of blood were collected at 0, 1, 2, and 4 h after dosing. Plasma ARS and dihydroartemisinin (DHA) were measured using high-performance liquid chromatography-mass spectrometry (LC-MS).
RESULTS: Results did not show evidence of time-dependency for ARS or the active plasma metabolite DHA. There were no differences in the concentrations of ARS and DHA at all sampling times on days 1 and 5. In addition, the pharmacokinetics of both compounds were similar on days 1 and 5. This finding confirms that the enzyme auto-induction in drug metabolism may not be characteristic of the endoperoxide sesquiterpene antimalarial group.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18600318     DOI: 10.1007/s00228-008-0506-6

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  20 in total

Review 1.  Artemisinin-based combination therapies (ACTs): best hope for malaria treatment but inaccessible to the needy!

Authors:  T K Mutabingwa
Journal:  Acta Trop       Date:  2005-09       Impact factor: 3.112

2.  Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin.

Authors:  U S Svensson; M Ashton
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

3.  Artemisinin pharmacokinetics is time-dependent during repeated oral administration in healthy male adults.

Authors:  M Ashton; T N Hai; N D Sy; D X Huong; N Van Huong; N T Niêu; L D Công
Journal:  Drug Metab Dispos       Date:  1998-01       Impact factor: 3.922

4.  Declining concentrations of dihydroartemisinin in plasma during 5-day oral treatment with artesunate for Falciparum malaria.

Authors:  N X Khanh; P J de Vries; L D Ha; C J van Boxtel; R Koopmans; P A Kager
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

5.  Artemisinin induces omeprazole metabolism in human beings.

Authors:  U S Svensson; M Ashton; N H Trinh; L Bertilsson; X H Dinh; V H Nguyen; T N Nguyen; D S Nguyen; J Lykkesfeldt; D C Le
Journal:  Clin Pharmacol Ther       Date:  1998-08       Impact factor: 6.875

6.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.

Authors:  T Shimada; H Yamazaki; M Mimura; Y Inui; F P Guengerich
Journal:  J Pharmacol Exp Ther       Date:  1994-07       Impact factor: 4.030

7.  A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens.

Authors:  Doaa A Elsherbiny; Sara A Asimus; Mats O Karlsson; Michael Ashton; Ulrika S H Simonsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-03-19       Impact factor: 2.745

8.  Reduced hepatic blood flow and intestinal malabsorption in severe falciparum malaria.

Authors:  M E Molyneux; S Looareesuwan; I S Menzies; S L Grainger; R E Phillips; Y Wattanagoon; R P Thompson; D A Warrell
Journal:  Am J Trop Med Hyg       Date:  1989-05       Impact factor: 2.345

9.  Clinical efficacy and pharmacokinetics of artemisinin monotherapy and in combination with mefloquine in patients with falciparum malaria.

Authors:  M H Alin; M Ashton; C M Kihamia; G J Mtey; A Björkman
Journal:  Br J Clin Pharmacol       Date:  1996-06       Impact factor: 4.335

10.  Pharmacokinetics of artesunate after single oral administration to rats.

Authors:  P L Olliaro; N K Nair; K Sathasivam; S M Mansor; V Navaratnam
Journal:  BMC Pharmacol       Date:  2001-12-20
View more
  14 in total

1.  Pharmacokinetics and ex vivo antimalarial activity of artesunate-azithromycin in healthy volunteers.

Authors:  Nguyen Trong Chinh; Nguyen Ngoc Quang; Chu Xuan Anh; Nguyen Xuan Thanh; Bui Dai; Geoffrey W Birrell; Marina Chavchich; Michael D Edstein
Journal:  Antimicrob Agents Chemother       Date:  2011-07-05       Impact factor: 5.191

2.  Antimalarial activity of the myxobacterial macrolide chlorotonil a.

Authors:  Jana Held; Tamirat Gebru; Markus Kalesse; Rolf Jansen; Klaus Gerth; Rolf Müller; Benjamin Mordmüller
Journal:  Antimicrob Agents Chemother       Date:  2014-08-11       Impact factor: 5.191

3.  Pharmacokinetics of chlorproguanil, dapsone, artesunate and their major metabolites in patients during treatment of acute uncomplicated Plasmodium falciparum malaria.

Authors:  Ann K Miller; Nibedita Bandyopadhyay; Daniel G Wootton; Stephan Duparc; Paula L Kirby; Peter A Winstanley; Stephen A Ward
Journal:  Eur J Clin Pharmacol       Date:  2009-06-11       Impact factor: 2.953

4.  Population pharmacokinetics of artesunate and dihydroartemisinin following single- and multiple-dosing of oral artesunate in healthy subjects.

Authors:  Beesan Tan; Himanshu Naik; In-Jin Jang; Kyung-Sang Yu; Lee E Kirsch; Chang-Sik Shin; J Carl Craft; Lawrence Fleckenstein
Journal:  Malar J       Date:  2009-12-18       Impact factor: 2.979

5.  Pharmacokinetics and pharmacodynamics of oral artesunate monotherapy in patients with uncomplicated Plasmodium falciparum malaria in western Cambodia.

Authors:  David Saunders; Phisit Khemawoot; Pattaraporn Vanachayangkul; Raveewan Siripokasupkul; Delia Bethell; Stuart Tyner; Youry Se; Wiriya Rutvisuttinunt; Sabaithip Sriwichai; Lon Chanthap; Jessica Lin; Ans Timmermans; Doung Socheat; Pascal Ringwald; Harald Noedl; Bryan Smith; Mark Fukuda; Paktiya Teja-Isavadharm
Journal:  Antimicrob Agents Chemother       Date:  2012-08-06       Impact factor: 5.191

6.  Population pharmacokinetics of artesunate and dihydroartemisinin during long-term oral administration of artesunate to patients with metastatic breast cancer.

Authors:  Therese Ericsson; Antje Blank; Cornelia von Hagens; Michael Ashton; Angela Äbelö
Journal:  Eur J Clin Pharmacol       Date:  2014-09-25       Impact factor: 2.953

7.  Pyronaridine-Artesunate (Pyramax) for Treatment of Artemisinin- and Piperaquine-Resistant Plasmodium falciparum in the Central Highlands of Vietnam.

Authors:  Nguyen Duc Manh; Nguyen Van Thanh; Huynh Hong Quang; Nguyen Thi Thanh Van; Nguyen Ngoc San; Nguyen Chinh Phong; Geoffrey W Birrell; Michael D Edstein; Kimberly A Edgel; Nicholas J Martin; Marina Chavchich
Journal:  Antimicrob Agents Chemother       Date:  2021-09-27       Impact factor: 5.191

8.  Pharmacokinetics, tissue distribution and mass balance of radiolabeled dihydroartemisinin in male rats.

Authors:  Lisa H Xie; Qigui Li; Jing Zhang; Peter J Weina
Journal:  Malar J       Date:  2009-05-26       Impact factor: 2.979

9.  Population Pharmacokinetic and Pharmacodynamic Modeling of Artemisinin Resistance in Southeast Asia.

Authors:  Jesmin Lohy Das; Arjen M Dondorp; Francois Nosten; Aung Pyae Phyo; Warunee Hanpithakpong; Pascal Ringwald; Pharath Lim; Nicholas J White; Mats O Karlsson; Martin Bergstrand; Joel Tarning
Journal:  AAPS J       Date:  2017-09-11       Impact factor: 4.009

10.  An investigation of the auto-induction of and gender-related variability in the pharmacokinetics of dihydroartemisinin in the rat.

Authors:  Fanping Zhu; Fuying Du; Xinxiu Li; Jie Xing
Journal:  Malar J       Date:  2012-11-21       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.